Ensartinib for advanced or metastatic non-small-cell lung cancer with MET exon 14 skipping mutations (EMBRACE): a multi-center, single-arm, phase 2 trial
This work was supported by the National Natural Science Foundation of China [82370028, 82422001] and the CSCO-MET Aberrant Solid Tumor Research Grant [Y-2022METAZMS-0066].
Authors
- Yuefei Lu
- Xiuning Le (ORCID: https://orcid.org/0000-0002-8554-1185)
- Zhiyuan Guo (ORCID: https://orcid.org/0000-0001-9557-9171)
- Yang Xia (ORCID: https://orcid.org/0000-0003-2487-2244)
- Panwen Tian (ORCID: https://orcid.org/0000-0002-6313-3228)
- Da Miao (ORCID: https://orcid.org/0000-0002-9283-279X)
- Wen Li (ORCID: https://orcid.org/0000-0002-8981-8380)
- Xiuzhen Li (ORCID: https://orcid.org/0000-0002-4900-9255)
- Jun Zhao (ORCID: https://orcid.org/0000-0003-1464-7158)
- Jin Yang
- Yongchang Zhang (ORCID: https://orcid.org/0000-0002-6829-7176)
- Mo Zhou (ORCID: https://orcid.org/0000-0002-1135-1848)
- Weina Lu
- Wanting Xu (ORCID: https://orcid.org/0000-0002-8714-5215)
Institutions
- Handan College (CN)
- The University of Texas MD Anderson Cancer Center (US)
- Central South University (CN)
- Peking University (CN)
- Peking University Cancer Hospital (CN)
- Zhejiang Cancer Hospital (CN)
- Hunan Cancer Hospital (CN)
- Sichuan Cancer Hospital (CN)
- Wuhan Union Hospital (CN)
- Second Affiliated Hospital of Zhejiang University (CN)
- Union Hospital (CN)
- Zhejiang University (CN)
Publication Details
- Journal
- EClinicalMedicine
- Published
- 2025-02-12
- DOI
- https://doi.org/10.1016/j.eclinm.2025.103099
- Citations
- 9
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 13.67
Funders
- National Natural Science Foundation of China
- Chinese Society of Clinical Oncology